MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.
MicroRNAs are often aberrantly expressed in human neoplasms and are postulated to play a role in neoplastic initiation and progression. miR-221 and miR-222 negatively regulate expression of CDKN1B (p27) and CDKN1C (p57), two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas. We characterized miR-221 and miR-222 expression in 49 sporadic high grade ovarian carcinomas and determined whether somatic mutation or epigenetic alterations explained the differences in expression of these miRNAs. We correlated these findings with protein expression of CDKN1B and CDKN1C as assessed by immunohistochemistry. Expression of miR-221 and miR-222 were closely correlated with each other (P = 0.0001). Interestingly, a lower ratio of miR-221 to miR-222 expression was significantly correlated with worse overall survival (P = 0.01) and remained a significant predictor of overall survival in multivariate analysis using the covariate adequacy of surgical cytoreduction (P = 0.03). Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression (P = 0.009 and 0.01). In contrast, CDKN1B expression was not associated with miR-221 or miR-222 expression. Neither somatic mutations nor methylation of the studied region explained the alterations in miR-221 and miR-222 expression in most carcinomas.
Wurz
Kaitlyn
K
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195-6460, USA.
Garcia
Rochelle L
RL
Goff
Barbara A
BA
Mitchell
Patrick S
PS
Lee
Jun Haeng
JH
Tewari
Muneesh
M
Swisher
Elizabeth M
EM
D002453:Cell Cycle / Q000235:genetics; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics; D050761:Cyclin-Dependent Kinase Inhibitor p57; D018450:Disease Progression; D015536:Down-Regulation; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D014158:Transcription, Genetic
D050760:Cyclin-Dependent Kinase Inhibitor p27; D050761:Cyclin-Dependent Kinase Inhibitor p57; D035683:MicroRNAs; C493964:CDKN1C protein, human; C525709:MIR221, human; C525710:MIR222, human
EMBO J. 2007 Aug 8;26(15):3699-708
17627278
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41
16754881
Int J Gynecol Pathol. 2007 Oct;26(4):418-25
17885492
N Engl J Med. 2008 Dec 18;359(25):2641-50
19092150
Hum Pathol. 2001 Aug;32(8):808-13
11521224
Cancer Res. 2007 Sep 15;67(18):8699-707
17875710
Nucleic Acids Res. 2005 May 12;33(8):2697-706
15891114
Oncogene. 2008 Sep 25;27(43):5651-61
18521080
Clin Cancer Res. 2003 Oct 15;9(13):4811-8
14581352
Cancer Res. 2008 Apr 15;68(8):2773-80
18413744
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9
18458333
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61
18768788
Cell. 2004 Jan 23;116(2):281-97
14744438
Cell Cycle. 2007 Aug 15;6(16):2005-9
17721077
Clin Cancer Res. 1999 Oct;5(10):2848-53
10537352
Gynecol Oncol. 1999 May;73(2):202-9
10329035
Anticancer Res. 2002 Nov-Dec;22(6A):3191-6
12530064
Cancer Res. 1999 Aug 1;59(15):3790-4
10446997
PLoS One. 2008 Jun 18;3(6):e2436
18560586
BMC Cancer. 2008 Mar 06;8:68
18325103
Cell. 2009 Jan 23;136(2):215-33
19167326
PLoS One. 2009;4(4):e5311
19390579
Trends Mol Med. 2006 Dec;12(12):580-7
17071139